The Pharmacy Times® Women's Health Resource Center is a comprehensive resource for clinical news and expert insights on issues related to health conditions that affect women, including gynecological health and maternal health.
Study: Pregnant Women With COVID-19 Face Greater Risk of Hospitalization, ICU Admission
Findings show that key factors include age, infecting variant, underlying illnesses, and vaccination status.
Pharmacists Play an Essential Role in Patients’ Access to Contraception
Legislation allowing pharmacists to prescribe contraceptives is becoming more widespread.
FDA Approves Osteseconazole for Recurrent Vulvovaginal Candidiasis
Osteseconazole (Vivjoa) is the first FDA-approved treatment for recurrent vulvovaginal candidiasis, also known as chronic yeast infection, in women with a history of the condition who are not of reproductive potential.
Bijuva From TherapeuticsMD
TherapeuticsMD, Inc has submitted a supplemental New Drug Application for estradiol and progesterone capsules 0.5 mg/100 mg (Bijuva) to the FDA.
California Requires State Universities to Offer Access to Medication Abortion on Campus
32 public colleges with combined enrollment of more than 700,000 students must comply with law by January 2023.
Daily OTC Pearl: Premsyn PMS
Premsyn PMS temporarily relieves symptoms associated with premenstrual syndrome.
Hepatitis C Is Widespread but Rarely Treated in Postpartum Medicaid Beneficiaries With OUD
Getting an appointment with an infectious diseases specialist, particularly after giving birth and while managing a chronic disorder, such as substance use, is difficult, investigators say.
Endocrine Therapy May Benefit Women in Postmenopause as Much as Chemoendocrine
21-gene profiling is also preferred for patients with 1 to 3 pathologically positive lymph nodes, according to a presentation at the Hematology/Oncology Pharmacy Association conference.
Women Are Less Likely to Receive Life-Saving Heart Procedures, Study Results Show
They are also at greater risk of death than men when undergoing cardiac procedures, a new analysis shows.
FDA Approves Pembrolizumab for MSI‑H/dMMR Advanced Endometrial Carcinoma
Pembrolizumab (Keytruda) approved as a single agent for the treatment of patients with microsatellite instability–high or mismatch repair deficient advanced endometrial carcinoma.
Approaching Treatment of Newly Diagnosed or Recurrent Ovarian Cancer With PARP Inhibitors
Only 40% of patients with platinum sensitive disease are receiving a PARP inhibitor in the first-line setting.
Assessing Therapeutic Approach to Treatment-Naïve Advanced Ovarian Cancer
Data from the SOLO-1 trial highlight that even with an excellent prognostic group, patients with ovarian cancer still benefit from the use of a PARP inhibitor.
With New Options for the Treatment of Cervical Cancer, Considering Individual Patient Characteristics is Essential
The death rate from cervical cancer has dropped by more than 50% since 1975.
Pivotal Trial Supports Use of Mirvetuximab Soravtansine in Ovarian Cancer
Use of mirvetuximab soravtansine monotherapy in patients with ovarian cancer resulted in meaningful anti-tumor activity, consistent safety, and favorable tolerability.
Expert: Pharmacists Can Find Solutions for Overspending Driven by Dose-Specific Packaging
Pharmacists are essential partners in solving overspending caused by dose-specific packaging of lenvatinib.
Experience of Racism Associated With Negative Effects on Cancer Care Delivery for Black Women With Gynecologic Malignancies
Black women are at an increased risk of dying from cancer of any type compared to White women, but gynecologic cancers have some of the widest survival gaps.
Hormone Replacement Therapy Can Benefit Some Patients with Gynecologic Cancers
Hormone replacement therapy can improve quality of life without necessarily increasing the risk of recurrence.
Black, Hispanic Patients Underrepresented in Clinical Trials Cited in NCCN Guidelines for Endometrial Cancer Systemic Therapy Regimens
Although poorer prognoses are common for all patients with advanced and recurrent endometrial cancers, minority populations are disproportionately affected with higher rates of mortality.
Dose-Specific Packaging for Lenvatinib in Endometrial Cancer Could Improve Adherence, But Drives Overspending
Lenvatinib was approved in July of 2021 for the treatment of microsatellite-stable advanced endometrial cancer after platinum-based chemotherapy.
SGO 2022 Opening Ceremony Celebrates Innovation, Resilience Throughout Pandemic
Speakers at the annual Society of Gynecologic Oncology annual meeting emphasized the theme of building bridges and breaking barriers to advance gynecologic care.
Overview of Key Developments in the Field of Gynecologic Oncology at the SGO Annual Meeting
S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses some key developments in the field of gynecologic oncology that will be on the agenda at the SGO 2022 annual meeting.
Antiseptic Drugs May Serve as Alternatives to Antibiotics to Prevent UTIs, Study Results Show
The medications may also help tackle the global problem of antibiotic resistance, investigators say.
Study Results Show Possible Link Between Hormone Levels Before Birth and Migraine Risk
Analysis assessing data from the world’s largest twin registry also finds evidence that genetic factors for strong headaches may differ between men and women.
Report Emphasizes Need for Group B Streptococcus Vaccine
The global impact of GBS causes approximately 150,000 deaths of babies each year.
How Pharmacists Can Help Lower Infants’ Leading Cause of Death
It is essential that women are informed of the risks of potentially teratogenic medications because most birth defects are likely to happen early in pregnancy before women become aware they are pregnant.
Society of Gynecologic Oncology President Outlines Initiatives for Her Tenure
Dr. Seiko Diane Yamada, MD, the 53rd president of Society of Gynecologic Oncology (SGO), discussed her goals for SGO during her tenure.
Study: Women With Migraines Show Higher Risk of Pregnancy Complications
Although the risks are still, individuals with a history of migraines should be aware of and consult with their physicians, investigators say.
Overview of Hypoactive Sexual Desire Disorder Treatments Currently Available, in the Pipeline
Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses the treatments for hypoactive sexual desire disorder currently available and those not yet approved.
Expert: ‘We're Lagging Behind on the Biology Piece’ of Women’s Sexual Health Conditions
Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses the origin of the historical idea that sexual dysfunction in women is primarily based in emotional and/or psychological conditions.
Expert: Women’s Sexual Health Treatments Have Remained Psychosocial, While Men’s Sexual Health Treatments Have Progressed in the Biological
Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses how hypoactive sexual desire disorder in women was defined and treated historically.
2 Clarke Drive Cranbury, NJ 08512